Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

Thumbnail

When TEER fails, most patients require mitral valve replacement

The team's findings were presented at the 101st Annual Meeting of the American Association for Thoracic Surgery and published in the Journal of the American College of Cardiology.

SCAI 2021: Harmony TPV could ‘fundamentally alter’ care for patients with congenital heart disease

Overall, one-year findings showed that there were no instances of mortality, endocarditis, major stent fractures or surgical intervention among patients who received the Harmony TPV.

Thumbnail

SCAI 2021: 98% of new TAVR programs developed in metropolitan areas

Researchers tracked 554 TAVR programs that opened from 2012 to 2018, sharing their findings at the SCAI 2021 Scientific Sessions.

Thumbnail

Transseptal MViV for high-risk patients associated with 100% success rate after 1 year

Researchers explored data from one arm of the MITRAL early feasible study, sharing their findings in JACC: Cardiovascular Interventions. 

Thumbnail

TEER still beneficial for heart failure patients with an elevated mitral valve gradient

Researchers explored data from the COAPT trial, sharing their findings in JACC: Cardiovascular Interventions.

Thumbnail

Surgical risk scores may not be needed when considering TAVR

Recent TAVR research suggests clinicians should focus on other key factors such as the patient's age and life expectancy. 

Thumbnail

Risk of death, stroke increases with age for TAVR patients

The risk of post-TAVR pacemaker implantation also goes up when treating elderly patients. 

COVID-19 patients undergoing TAVR may face a higher risk of death

The study included data from more than 3,000 TAVR patients who received care from January 2020 to January 2021. 

Around the web

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.